Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie for å undersøke den kliniske effekten og sikkerheten av PRX-115 infundert intravenøst med ulike doseringsregimer, med og uten metotreksat, kontra placebo hos voksne pasienter med gikt (RELEASE) (RELEASE)

28. september 2026 oppdatert av: Protalix

Et multicenter, randomisert, dobbeltblindet, placebokontrollert, fase 2-studie som vurderer effekt, sikkerhet og doseringsregimvalg av multiple intravenøse infusjoner av PRX-115 med og uten metotreksat versus placebo hos voksne pasienter med gikt (RELEASE)

This is a multicenter, randomized, double-blind, placebo-controlled phase II study assessing the efficacy, safety, and dosing regimen selection of multiple IV infusions of PRX-115 over 24 weeks, with or without MTX, versus the respective placebos in adult patients with gout.

Studieoversikt

Detaljert beskrivelse

This study will evaluate the efficacy, safety, tolerability, immunogenicity, pharmacokinetics (PK), and pharmacodynamics (PD) of PRX-115 (a recombinant pegylated Uricase) in adult patients with gout. Participants will receive PRX-115 by intravenous (IV) infusions according to different treatment schedules, with and without the immunomodulator methotrexate (MTX).

Studietype

Intervensjonell

Registrering (Antatt)

150

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Head of Clinical Development
  • Telefonnummer: +972-4-902-8100
  • E-post: info@protalix.com

Studiesteder

    • Arizona
      • Glendale, Arizona, Forente stater, 85306
        • Rekruttering
        • Rezen Clinical Trials
    • Arkansas
      • Little Rock, Arkansas, Forente stater, 72205
        • Rekruttering
        • Applied Research Center of Arkansas
    • California
      • Anaheim, California, Forente stater, 92805
        • Rekruttering
        • Advanced Research Center, Inc
      • El Cajon, California, Forente stater, 91910
        • Rekruttering
        • Triwest Research Associates Llc
      • La Palma, California, Forente stater, 90623
        • Rekruttering
        • Imax Clinical Trials, LLC
      • Long Beach, California, Forente stater, 90806
        • Rekruttering
        • Kinetic Clinical Research
    • Florida
      • Clearwater, Florida, Forente stater, 33765
        • Rekruttering
        • Clinical Research of West Florida, Inc.
      • DeLand, Florida, Forente stater, 32720
        • Rekruttering
        • Accel Research Sites - Deland Clinical Research Unit
      • Doral, Florida, Forente stater, 33125
        • Rekruttering
        • ICR Sites East
      • Hialeah, Florida, Forente stater, 33010
        • Rekruttering
        • Qway Research
      • Miami, Florida, Forente stater, 33155
        • Rekruttering
        • Bioclinical Research Alliance, Inc
      • Miami, Florida, Forente stater, 33169
        • Rekruttering
        • D&H National Research Centers (North Miami)
      • Miami, Florida, Forente stater, 33173
        • Rekruttering
        • Well Pharma Medical Research Group
      • Orlando, Florida, Forente stater, 32832
        • Rekruttering
        • Conquest Research - Lake Nona
      • Orlando, Florida, Forente stater, 32897
        • Rekruttering
        • Combined Research Orlando Phase I-IV
      • Palmetto Bay, Florida, Forente stater, 33176
        • Rekruttering
        • New Horizons Research
      • Tampa, Florida, Forente stater, 33606
        • Rekruttering
        • Clinical Research of West Florida, Inc.
    • Georgia
      • Columbus, Georgia, Forente stater, 31904
        • Rekruttering
        • Centricity Research - Columbus Georgia Multispecialty
    • Michigan
      • Dearborn, Michigan, Forente stater, 48126
        • Rekruttering
        • Revival Research Institute, LLC
      • Farmington Hills, Michigan, Forente stater, 48334
        • Rekruttering
        • Quest Research Institute
      • Sterling Heights, Michigan, Forente stater, 48313
        • Rekruttering
        • Revive Research Institute, Inc
    • Pennsylvania
      • Duncansville, Pennsylvania, Forente stater, 16635
        • Rekruttering
        • Altoona Center for Clinical Research
    • Texas
      • Houston, Texas, Forente stater, 77099
        • Rekruttering
        • Pioneer Research Solutions Inc
      • Sugar Land, Texas, Forente stater, 77479
        • Rekruttering
        • Mt. Olympus Medical Research, LLC - Sugar Land
      • Waco, Texas, Forente stater, 76710
        • Rekruttering
        • Velocity Clinical Research
    • Virginia
      • Suffolk, Virginia, Forente stater, 23435
        • Rekruttering
        • Velocity Clinical Research
      • Tbilisi, Georgia, 0102
        • Rekruttering
        • Aleksandre Aladashvili Clinic LLC, Georgia
      • Tbilisi, Georgia, 0159
        • Rekruttering
        • Tbilisi Heart and Vascular Clinic Ltd , Georgia
      • Tbilisi, Georgia, 0160
        • Rekruttering
        • Mediclub Georgia
      • Tbilisi, Georgia, 0160
        • Rekruttering
        • Tbilisi Institute of Medicine, Georgia
      • Tbilisi, Georgia, 0172
        • Rekruttering
        • Georgian-Dutch Hospital, Georgia
      • Tbilisi, Georgia, 0180
        • Rekruttering
        • LTD First Medical Center, Georgia
      • Afula, Israel, 1834111
        • Rekruttering
        • HaEmek MC, Israel
      • Ashkelon, Israel, 7830604
        • Rekruttering
        • Barzilai MC, Israel
      • Kfar Saba, Israel, 4438164
        • Rekruttering
        • Meir MC, Israel

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Males or females ≥18 years of age.
  2. Weight within the range of 50.0 - 150.0 kg.
  3. Gout patients who failed to normalize sUA (<7 mg/dL) with or without xanthine oxidase inhibitors or uricosuric agent or have contraindications to these drugs.
  4. Willing to discontinue any oral ULT
  5. Females who are sterile, postmenopausal, or non-pregnant and using birth control methods.

Exclusion Criteria:

  1. Any condition known to have arthritis as a clinical manifestation.
  2. Positive testing for HBV,HCV, or HIV.
  3. The patient is a pregnant or lactating female or plans to become pregnant during the study period.
  4. Known allergy or sensitivity to the injected proteins, including pegylated products.
  5. Prior exposure to any experimental or marketed uricase.
  6. Patient treated with a medication known to have an influence on urate metabolism or clearance such as ULTs.
  7. History of anaphylaxis, severe allergic reactions, or severe atopy.
  8. G6PD deficiency or known catalase deficiency.
  9. History of significant hematologic or autoimmune disorders within 5 years of Screening and/or patient is immunocompromised or treated with immunosuppressive medications.
  10. Non-compensated CHF or hospitalization for CHF (Stage 3-4 NYHA Functional Class) within 3 months of the Screening Visit, uncontrolled arrhythmia, treatment for acute coronary syndrome (myocardial infarction or unstable angina), or uncontrolled BP (>160/100 mmHg) at screening and prior to randomization at Week -4 (Visit 1).
  11. Current liver disease, as determined by ALT or AST levels above upper limit of normal at Screening Visit.
  12. Chronic liver disease.
  13. Hemoglobin <11 g/dL, neutrophil count <1500 /µl, or platelet count <100,000 /µl.
  14. Known severe pulmonary fibrosis, bronchiectasis or interstitial pneumonitis.
  15. eGFR ≤ 40 mL/min/1.73m2 tested at Screening Visit. Kidney transplant or requires dialysis.
  16. Known intolerance and/or known contraindication to MTX treatment or MTX treatment considered inappropriate
  17. Has uncontrolled type 2 diabetes at Screening with HbA1c ≥8.5%. Patients with type 1 diabetes will be excluded.
  18. Has known latent autoimmune diabetes of adult.
  19. Immunocompromised state, regardless of etiology.
  20. History or treatment of malignancy in the last 5 years, excluding localized, nonmelanoma skin cancers (e.g. basal or squamous cell)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: E4W with placebo-MTX

IV infusion of PRX-115 every 4 weeks (E4W) for a total of 6 doses with placebo-MTX

intravenous (IV) infusion

Oral Placebo-MTX weekly

Eksperimentell: E4W with MTX

IV infusion of PRX-115 every 4 weeks (E4W) for a total of 6 doses with MTX

intravenous (IV) infusion

Oral MTX 15 mg weekly

Eksperimentell: E6W with MTX

IV infusion of PRX-115 every 6 weeks (E6W) for a total of 4 doses with MTX

intravenous (IV) infusion

Oral MTX 15 mg weekly

Eksperimentell: E8W with MTX

IV infusion of PRX-115 every 8 weeks (E8W) for a total of 3 doses with MTX

intravenous (IV) infusion

Oral MTX 15 mg weekly

Placebo komparator: placebo E4W

infusion of PRX-115 placebo every 4 weeks (E4W) for a total of 6 doses with placebo-MTX

Oral Placebo-MTX weekly

intravenous (IV) infusion

Placebo komparator: placebo E6W

IV infusion of PRX-115 placebo every 6 weeks (E6W) for a total of 4 doses with placebo-MTX

Oral Placebo-MTX weekly

intravenous (IV) infusion

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6
Tidsramme: 6 months of treatment

Proportion of patients who achieve a reduction in sUA to <6.0 mg/dL for at least 80% of the time during Month 6

6 months of treatment

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) at different time points
Tidsramme: 3 to 6 months of treatment

Proportion of patients that achieve a reduction in sUA to <6.0 mg/dL for at least 80% of the time during Month 3 or 4, 5 and 6.

3 to 6 months of treatment
Treatment-emergent adverse events (TEAEs)
Tidsramme: From enrollment to 8 months of study

Occurrence and severity of treatment-emergent adverse events (TEAEs)

From enrollment to 8 months of study

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

22. desember 2025

Primær fullføring (Antatt)

1. desember 2027

Studiet fullført (Antatt)

1. juni 2028

Datoer for studieregistrering

Først innsendt

3. desember 2025

Først innsendt som oppfylte QC-kriteriene

3. desember 2025

Først lagt ut (Faktiske)

12. desember 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

29. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

28. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere